GlaxoSmithKline Inc.
GlaxoSmithKline Inc. has met with MPs 19 times since January 2024, reaching 15 MPs across 2 parties. Most recent contact: May 20, 2026.
What they're asking for
In the registry's own words. Descriptions are only filed for meetings since mid-2024.
Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.
May 20, 2026 · Jean-Yves Duclos · Liberal · Government Procurement; Health; Industry; International Trade; Economic Development
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy and policies and programming related to biomanufacturing in Canada
February 17, 2026 · Jean-Yves Duclos · Liberal · Health; Research and Development; Economic Development
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
November 25, 2025 · Burton Bailey · Conservative · Health; Research and Development
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
November 25, 2025 · Salma Zahid · Liberal · Health; Industry
Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030.
November 25, 2025 · Salma Zahid · Liberal · Health; Immigration
National Immunization Strategy and policies and programs that impact public access to vaccines and disease prevention in Canada.
November 12, 2025 · Jeff Kibble · Conservative · Health
Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada.
October 10, 2025 · Rachael Thomas · Conservative · Health
Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.
July 22, 2025 · Dan Mazier · Conservative · Health; International Trade; Economic Development
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy
November 29, 2024 · François-Philippe Champagne · Liberal · Health; Research and Development; Economic Development
Full meeting log
19 MP-directed communications since January 2024, from the Registry of Lobbyists.
| Date | MP |
|---|---|
| 2026-05-20 | Jean-Yves Duclos · Liberal |
| 2026-02-17 | Jean-Yves Duclos · Liberal |
| 2025-11-25 | Burton Bailey · Conservative |
| 2025-11-25 | Salma Zahid · Liberal |
| 2025-11-25 | Salma Zahid · Liberal |
| 2025-11-12 | Jeff Kibble · Conservative |
| 2025-10-10 | Rachael Thomas · Conservative |
| 2025-10-06 | Warren Steinley · Conservative |
| 2025-09-03 | Iqra Khalid · Liberal |
| 2025-09-03 | Salma Zahid · Liberal |
| 2025-07-22 | Dan Mazier · Conservative |
| 2025-06-24 | Helena Jaczek · Liberal |
| 2025-05-23 | Ruby Sahota · Liberal |
| 2024-11-29 | François-Philippe Champagne · Liberal |
| 2024-11-22 | Jean-Yves Duclos · Liberal |
| 2024-09-24 | Shuvaloy Majumdar · Conservative |
| 2024-09-23 | Yasir Naqvi · Liberal |
| 2024-06-13 | Tom Kmiec · Conservative |
| 2024-03-15 | Anita Anand · Liberal |